SymBiosis is a venture capital firm investing in bioengineering with a focus on advanced therapies for life-threatening diseases. The company partners with innovators in novel biologics, cell and gene therapies, and precision small molecules, leveraging high-throughput biology and computational drug discovery. SymBiosis emphasizes long-term partnerships from pre-IND to commercialization, aiming to transform today's medicines with industrial scale and speed.
Recent Transactions involving SymBiosis
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
QIA invests in Ensoma, a genomic medicines company |
Ensoma |
Bill & Melinda Gates Foundation Strategic Investment FundArix BioscienceSolasta VenturesF-Prime CapitalTakeda VenturesSymBiosisAlexandria Venture InvestmentsFred Hutchinson Cancer CenterQatar Investment AuthorityCatalio Capital ManagementMirae Asset Financial GroupCormorant Asset ManagementViking Global Investors |
Biotechnology Research |
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →